Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe
23 mai 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016
16 mai 2016 17h09 HE
|
AIM ImmunoTech Inc.
The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the...
Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016
12 mai 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 12, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 first quarter...
Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®
20 avr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the "Company” or "Hemispherx”) announced that it has signed a consulting agreement with Huron Consulting...
Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease
04 avr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, April 04, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution,...
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015
29 mars 2016 17h41 HE
|
AIM ImmunoTech Inc.
Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueConference...
Hemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016
22 mars 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates releasing its 2015 year-end financial...
Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)
10 mars 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...
Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value
22 févr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has announced that the Board of Directors has made several changes to its...
Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)
09 févr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and...